Investor Relations

company profile oval

Corporate Profile

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates omaveloxolone and bardoxolone methyl target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.


Latest News

More News

Events and Presentations

More Events

Featured Presentation